TY - JOUR
T1 - Patient factors associated with quality of life in atrial fibrillation
AU - Randolph, Tiffany C.
AU - Simon, Da Juanicia N.
AU - Thomas, Laine
AU - Allen, Larry A.
AU - Fonarow, Gregg C.
AU - Gersh, Bernard J.
AU - Kowey, Peter R.
AU - Reiffel, James A.
AU - Naccarelli, Gerald V.
AU - Chan, Paul S.
AU - Spertus, John A.
AU - Peterson, Eric D.
AU - Piccini, Jonathan P.
N1 - Funding Information:
The ORBIT AF registry is sponsored by Janssen Scientific Affairs, LLC, Raritan, NJ. Dr. Randolph was funded by National Institutes of Health T-32 Training Grant No. T32 HL 69749–11 Al. Dr. Chan received funding from the National Heart, Lung, and Blood Institute (1R01HL123980).
Funding Information:
This research was sponsored by Janssen Scientific Affairs, LLC, Raritan, NJ. The authors are solely responsible for the design and conduct of this study, all study analyses, the drafting and editing of the paper and its final contents.
Funding Information:
Fonarow reports modest consultant support from Janssen and Medtronic. Gersh reports: consulting support from Janssen, Xenon, Cipla Limited and Armethoen, Inc.; DSMB for Mount Sinai, St. Lukes, Boston Scientific, Teva Pharmaceutical Industries, St. Jude Medical, Janssen Research and Development, Baxter Healthcare Corporation, Cardiovascular Research Foundation, and Thrombosis Research Institute; advisory board for Medtronic. Kowey reports modest consultant support from Jonhnson and Johnson. Naccarelli reports consultancies with Pfizer, Sanofi, Boehringer-Ingelheim, Bristol Myers Squibb, Otsuka, Janssen, Daiichi-Sankyo, Xention, Astra Zeneca and Glaxo Smith Kline. Peterson reports research support from Janssen and consultancies with Janssen, Boehringer Ingelheim, Sanofi, Bayer, Astra Zeneca, and Merckiccini. Piccini reports: consulting for GSK, Johnson & Johnson, Medtronic, and Spectranetics; research funding from ARCA biopharma, Boston Scientific, Gilead, Janssen Pharmaceuticals, ResMed, and St. Jude Medical. Spertus reports no direct conflicts with this work. Spertus reports: consultancies with Novartis, Regeneron, Bayer, and Amgen; research grant support from Lilly, Gillea, Genetech, ACCF; ownership interest in Health Outcomes Sciences and Copyright – SAQ, KCCQ, PAQ.
Publisher Copyright:
© 2016 Elsevier, Inc.
PY - 2016/12/1
Y1 - 2016/12/1
N2 - As treatment options for atrial fibrillation (AF) increase, more attention is focused on patients' experiences and quality of life (QoL). However, little is known about the factors associated with these outcomes. Methods The Atrial Fibrillation Effect on QualiTy-of-life (AFEQT) is a disease-specific QoL tool for AF, with domain and summary scores ranging from 0 (the worst QoL) to 100. Using multivariable linear regression, we evaluated factors associated with baseline AFEQT Summary and Subscale Scores in ORBIT AF, a large, community-based AF registry. Independent associations were reported as coefficient estimates in scores and 95% confidence intervals (CI). Results Overall, AFEQT was assessed in 2007 AF outpatients from 99 sites. Median age (IQR) was 76 years (67–82) and 43% were female. The median AFEQT summary score was 82 (67–94). Female sex, younger age, new onset AF, higher heart rate, obstructive sleep apnea, symptomatic heart failure (HF), chronic obstructive pulmonary disease and coronary artery disease were all independently associated with reduced QoL. Female sex [Estimate −7.03, 95% CI (−9.31, −4.75)] and new onset versus permanent AF [Estimate −7.44, 95% CI (−11.03, −3.84)] were independently associated with increased symptoms. NYHA Class III or IV HF [Estimate −14.44, 95% CI (−19.46, −8.76)] and female sex [Estimate −7.91, 95% CI (−9.95, −5.88)] were most independently associated with impaired daily activities. Conclusions QoL in patients with AF varies widely and is associated with several patient factors. Understanding patient factors independently associated with worse QoL can be a foundation for tailoring treatment.
AB - As treatment options for atrial fibrillation (AF) increase, more attention is focused on patients' experiences and quality of life (QoL). However, little is known about the factors associated with these outcomes. Methods The Atrial Fibrillation Effect on QualiTy-of-life (AFEQT) is a disease-specific QoL tool for AF, with domain and summary scores ranging from 0 (the worst QoL) to 100. Using multivariable linear regression, we evaluated factors associated with baseline AFEQT Summary and Subscale Scores in ORBIT AF, a large, community-based AF registry. Independent associations were reported as coefficient estimates in scores and 95% confidence intervals (CI). Results Overall, AFEQT was assessed in 2007 AF outpatients from 99 sites. Median age (IQR) was 76 years (67–82) and 43% were female. The median AFEQT summary score was 82 (67–94). Female sex, younger age, new onset AF, higher heart rate, obstructive sleep apnea, symptomatic heart failure (HF), chronic obstructive pulmonary disease and coronary artery disease were all independently associated with reduced QoL. Female sex [Estimate −7.03, 95% CI (−9.31, −4.75)] and new onset versus permanent AF [Estimate −7.44, 95% CI (−11.03, −3.84)] were independently associated with increased symptoms. NYHA Class III or IV HF [Estimate −14.44, 95% CI (−19.46, −8.76)] and female sex [Estimate −7.91, 95% CI (−9.95, −5.88)] were most independently associated with impaired daily activities. Conclusions QoL in patients with AF varies widely and is associated with several patient factors. Understanding patient factors independently associated with worse QoL can be a foundation for tailoring treatment.
UR - http://www.scopus.com/inward/record.url?scp=84992740899&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84992740899&partnerID=8YFLogxK
U2 - 10.1016/j.ahj.2016.08.003
DO - 10.1016/j.ahj.2016.08.003
M3 - Article
C2 - 27914493
AN - SCOPUS:84992740899
VL - 182
SP - 135
EP - 143
JO - American Heart Journal
JF - American Heart Journal
SN - 0002-8703
ER -